Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland

Swiss Medical Weekly

Volumn 140, Issue JULY, 2010, Pages

  Nicoletti, Joëlle ^a   Kuster, Stefan P ^a   Sulser, Tullio ^a   Zbinden, Reinhard ^b   Ruef, Christian ^a   Ledergerber, Bruno ^a   Weber, Rainer ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antibacterial drug resistance; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Urinary tract infections; Urology

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; QUINOLONE DERIVATIVE; URINARY TRACT ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BLADDER CATHETERIZATION; BLOOD CULTURE; CROSS-SECTIONAL STUDY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT; RECURRENT INFECTION; RISK ASSESSMENT; STRUCTURED QUESTIONNAIRE; SWITZERLAND; TERTIARY HEALTH CARE; URINARY TRACT INFECTION; URINE CULTURE; ACUTE DISEASE; AGED; BACTEREMIA; BACTERIURIA; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; HOSPITAL DEPARTMENT; MALE; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; RECURRENT DISEASE; RISK; RISK FACTOR; UNIVERSITY HOSPITAL;

ACUTE DISEASE; AGED; ANTI-INFECTIVE AGENTS, URINARY; BACTEREMIA; BACTERIURIA; CIPROFLOXACIN; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RECURRENCE; RISK FACTORS; SWITZERLAND; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS; UROLOGY DEPARTMENT, HOSPITAL;

EID: 84855954462     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2010.13059     Document Type: Article

References (29)

1. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227-41. (Pubitemid 36760181)
2. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135(1):41-50. (Pubitemid 32619282)
3. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother. 2000;46(Suppl A):49-52.
4. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 2001;357(9271):1851-3. (Pubitemid 32539121)
5. Ena J, Lopez-Perezagua MM, Martinez-Peinado C, Cia-Barrio MA, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis. 1998;30(2):103-7.
6. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87. (Pubitemid 40247914)
7. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51(1):69-76. (Pubitemid 36163829)
8. Kresken M, Hafner D, Mittermayer H, Verbist L, Bergogne-Berezin E, Giamarellou H, et al. Prevalence of fluoroquinolone resistance in Europe. Study Group "Bacterial Resistance" of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection. 1994;22(Suppl 2):S90-8.
9. Alos JI, Serrano MG, Gomez-Garces JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect. 2005;11(3):199-203. (Pubitemid 40352766)
10. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56(5):914-8. (Pubitemid 41631917)
11. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153(1):117-20. (Pubitemid 24379811)
12. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38(7-8):1148-52. (Pubitemid 38802150)
13. Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol. 2001;39(2):438-44. (Pubitemid 32150799)
14. Kuster SP, Ruef C, Zbinden R, Gottschalk J, Ledergerber B, Neuber L, et al. Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. J Antimicrob Chemother. 2008;62(6):1451-61.
15. Clarddige JE, Johnson JR, Pezzlo M. Laboratory diagnosis of urinary tract infections. Cumitech 3B. American Society for Microbiology, Washington, D.C. Cumitech 3B American Society for Microbiology, Washington, DC. 1998.
16. Clinical and Laboratory Standards Institute. 2008. Performance Standards for Antimicrobial Susceptibility Testing; Eigtheenth Informational Supplement 100-S18. Clinical and Laboratory Standards Instiute, Wayne, PA, USA.
17. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol. 2005;161(5):483-93. (Pubitemid 40315619)
18. Ti TY, Kumarasinghe G, Taylor MB, Tan SL, Ee A, Chua C, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis. 2003;22(4):242-5. (Pubitemid 36578910)
19. Richards DA, Toop LJ, Chambers ST, Sutherland MG, Harris BH, Ikram RB, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J. 2002;115(1146):12-4. (Pubitemid 34126304)
20. van Hees BC, de Ruiter E, Wiltink EH, de Jongh BM, Tersmette M. Optimizing use of ciprofloxacin: a prospective intervention study. J Antimicrob Chemother. 2008;61(1):210-3.
21. Feucht CL, Rice LB. An interventional program to improve antibiotic use. Harvey Whitney Books; 2003. p. 646-51.
22. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother. 2003;52(6):1005-10. (Pubitemid 38008423)
23. Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, Petit PL, et al. Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. J Antimicrob Chemother. 2000;46(2):223-8. (Pubitemid 30639291)
24. Gagliotti C, Nobilio L, Moro ML. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples. Clin Microbiol Infect. 2007;13(3):328-31. (Pubitemid 46603368)
25. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy. 2006;78(1):77-92. (Pubitemid 44108323)
26. anresis.ch - Sentinel Surveillance of Antibiotic Resistance in Switzerland [Internet]. University of Bern. c2005 - [cited 2009 Oct 10]. Available from: www.search.ifik.unibe.ch.
27. Baquero F. Resistance to quinolones in gram-negative microorganisms: mechanisms and prevention. Eur Urol. 1990;17(Suppl 1):3-12. (Pubitemid 20138472)
28. Vila J, Ruiz J, Marco F, Barcelo A, Goni P, Giralt E, et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994;38(10):2477-9. (Pubitemid 24304253)
29. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2003;47(10):3222-32. (Pubitemid 37229582)